238120.KQ Aligned Genetics Inc
- Market cap
- KRW 36.4B
- P/E
- 7.6x
- P/B
- 0.93x
- ROE
- 11.1%
- Dividend yield
- -
- Fundamental score
- 2.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 238120.KQ undervalued?
Graham number238120.KQ trades 44.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aligned Genetics Inc fundamental analysis
13 of 22 checks passedROE 1/2
Moderate return on equity (11.1%), between 10% and 20%.
ROA 1/1
Return on assets (7.2%) is above the industry median (1.4%).
Profit Consistency 2/2
Profitable for 7 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-27.9%) is not above the 5-year average (26.0% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-27.9%) is below the industry median (1.8%).
Revenue Growth 1/2
Revenue grew 5.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (30.1%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 10.1x against interest expense, well covered.
PE vs Market 1/1
PE (7.6x) is below the market median (11.3x).
PE vs Industry 1/1
PE (7.6x) is below the industry median (11.4x).
PBV 0/1
Price to book (0.9x) is above the industry median (0.9x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 7.0, limit 22.5).
PEG 1/1
PEG on 5-year earnings growth is 0.29, growth is cheap.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Aligned Genetics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aligned Genetics Inc
Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genetics, Inc. was founded in 2008 and is headquartered in Anyang-Si, South Korea.
Full company profileAligned Genetics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aligned Genetics Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.71B | 5.64B | 5.68B | 7.79B | 7.96B | 11.8B | 13.8B | 15.2B | 15.8B | 16.0B | 16.0B |
| Gross Profit | 2.52B | 3.60B | 3.36B | 4.61B | 4.54B | 7.35B | 8.77B | 10.7B | 11.2B | 11.2B | 11.9B |
| Operating Income | -1.67B | -1.85B | -1.92B | -399M | -253M | 2.18B | 2.85B | 3.34B | 2.78B | 2.44B | 1.75B |
| EBITDA | - | - | - | - | - | - | 3.26B | 4.27B | 5.29B | 3.36B | 4.30B |
| Net Income | -1.56B | -1.75B | -1.59B | 117M | 468M | 5.54B | 2.33B | 3.24B | 4.13B | 2.91B | 4.33B |
| EPS | -218 | -244 | -221 | 16 | 65 | 385 | 162 | 225 | 287 | 207 | 308 |
| Balance Sheet | |||||||||||
| Total Assets | 25.9B | 24.3B | 23.0B | 24.6B | 25.5B | 34.5B | 36.9B | 40.9B | 44.3B | 57.8B | 60.4B |
| Total Liabilities | 1.68B | 1.67B | 2.11B | 3.65B | 4.02B | 7.48B | 8.05B | 9.62B | 8.78B | 20.6B | 21.2B |
| Shareholders' Equity | 24.2B | 22.6B | 20.9B | 21.0B | 21.5B | 27.0B | 28.8B | 31.3B | 35.5B | 37.2B | 39.2B |
| Cash & Short-term Investments | 21.6B | 19.7B | 13.8B | 13.9B | 12.1B | 13.1B | 13.7B | 14.9B | 18.0B | 14.6B | 11.4B |
| Total Debt | - | - | - | 994M | 917M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.14B | -877M | -1.75B | 659M | 35.7M | 136M | 2.22B | 2.85B | 3.07B | 3.61B | 906M |
| Capital Expenditure | 865M | 405M | 213M | 262M | 96.4M | 3.31B | 2.00B | 880M | 340M | 12.9B | 516M |
| Free Cash Flow | - | - | - | 134M | -69.8M | -4.73B | 219M | 1.97B | 2.66B | -9.30B | 390M |
| Ratios | |||||||||||
| ROE | -6.4% | -7.7% | -7.6% | 0.6% | 2.2% | 20.5% | 8.1% | 10.3% | 11.6% | 7.8% | 11.1% |
| ROA | -6.0% | -7.2% | -6.9% | 0.5% | 1.8% | 16.1% | 6.3% | 7.9% | 9.3% | 5.0% | 7.2% |
| Net Profit Margin | -33.0% | -31.1% | -28.0% | 1.5% | 5.9% | 47.1% | 17.0% | 21.3% | 26.2% | 18.2% | 27.1% |
| Debt to Equity | - | - | - | 0.05x | 0.04x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aligned Genetics Inc dividends
Aligned Genetics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Nov 7, 2023.
Who owns Aligned Genetics Inc
- Insiders 40.44%
- Institutions 11.34%
- Public & others 48.22%
- Shares outstanding 14.2M
- Free float 6.78M
Aligned Genetics Inc company profile
- Company name
- Aligned Genetics Inc
- Ticker
- 238120.KQ
- ISIN
- KR7238120000
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 64
- Fiscal year end
- December
- Address
- 28 Simindaero, Anyang-Si, South Korea, 14055
- Phone
- 82 3 1478 4185
- Website
- alignedgenetics.com
About Aligned Genetics Inc
Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genetics, Inc. was founded in 2008 and is headquartered in Anyang-Si, South Korea.
Aligned Genetics Inc management
6- Mr. Yeon-Cheol JungChief Executive Officer · born 1970
- Mr. Keun-Chang ChoDirector of Research and Director · born 1968
- Mr. Byong-Seung ChoDirector of Planning and Director · born 1972
- Mr. Yeon-Seok JungDirector of Management and Director · born 1973
- Mr. Sung-Cheol ParkExecutive Director of Business Consulting and Director · born 1964
- Mr. Nu-Ri JeonDirector of Business Consulting and Director · born 1969